Sequenom CMM's MaterniT21 PLUS Testing Service Received Clinical Laboratory Permit From New York State

Citation metadata

Date: Aug. 24, 2013
Publisher: NewsRX LLC
Document Type: Article
Length: 407 words
Lexile Measure: 1620L

Document controls

Main content

Article Preview :

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, announced that the New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program (CLEP) has issued a clinical laboratory permit to allow the Sequenom Center for Molecular Medicine's (Sequenom CMM) San Diego facility to provide its noninvasive prenatal laboratory-developed test, the MaterniT21™ PLUS test, to healthcare professionals in the state of New York, effective August 1, 2013 (see also Biotechnology Companies).

In addition, Sequenom CMM's CLIA laboratory location in North Carolina has received accreditation...

Source Citation

Source Citation   

Gale Document Number: GALE|A340660915